Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
June 27 2022 - 8:00AM
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”),
a company focused on rare cancer therapeutics and formerly known as
Rafael Pharmaceuticals, today announced that data on its lead
compound CPI-613® (devimistat) in combination with gemcitabine and
nab-paclitaxel in patients with locally advanced or metastatic
pancreatic cancer will be presented at the European Society of
Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer
2022, taking place June 29 through July 2, 2022 in Barcelona,
Spain.
“We are excited to share updates from our
open-label phase 1 study for devimistat in pancreatic cancer at
ESMO,” said Sanjeev Luther, President & CEO of Cornerstone
Pharmaceuticals. “From their frontline experience treating cancer
and evaluating devimistat, Dr. Alistar and her team at Atlantic
Health are able to share perspectives on new treatment options,
including these results, which strengthen the hope that safer and
more effective treatment options are within reach.”
Poster Details:Poster Title: GA
CPI 613: A Single Arm, Open-Label Phase I Study of CPI-613 in
Combination with Gemcitabine and Nab-paclitaxel For Patients With
Locally Advanced or Metastatic Pancreatic Cancer
Authors: Angela Alistar, Bonny Morris, Sanjeev
Luther, Timothy Pardee, Neil Morganstein, Nicole Burak, Justin
Alpert
Devimistat’s mechanism of action aims to stunt
the growth of cancer cells, creating an opportunity to increase
survival rates for cancers like pancreatic, which have historically
produced grim outlooks for patients. Pancreatic cancer is the third
leading cause of cancer death in the United States, with current
standard of care treatments including moderate toxicity, and median
overall survival of less than 12 months.
“I’m pleased to share the results of this study
on devimistat for pancreatic cancer,” said Angela Alistar, M.D.,
Medical Director of Gastrointestinal Medical Oncology at Atlantic
Health System in New Jersey and principal investigator of the
study. “The results demonstrate that treatment with devimistat is
feasible, well tolerated and potentially clinically synergistic
with chemotherapy for patients with pancreatic adenocarcinoma. With
each milestone, we’re one step closer to delivering potential new
treatment options.”
Held at Atlantic Health System, the study was
comprised of a two-stage dose-escalation schema to evaluate the
maximum tolerated dose (MTD) of devimistat. 22 patients were
evaluated for at least six months of treatment. The treatment was
well-tolerated overall. The results prove that the treatment is
feasible. Further expansion of the combination in a multisite
setting is being evaluated.
About Cornerstone Pharmaceuticals,
Inc.Cornerstone Pharmaceuticals (“Cornerstone”) is
committed to the development of therapies for rare cancers that
have few to no treatment options available. Cornerstone’s lead
compound, CPI-613® (devimistat), is designed to target the
mitochondria of cancer cells in order to disrupt their energy
production, cutting off the fuel for disease growth. Devimistat is
undergoing multiple clinical trials and has been granted orphan
drug designation by the U.S. Food and Drug Administration (FDA) for
the following indications: Burkitt’s lymphoma, biliary tract
cancer, soft tissue sarcoma, myelodysplastic syndrome (MDS) and
peripheral T-cell lymphoma. In addition, the European Medicines
Agency (EMA) has granted orphan drug designation to devimistat for
Burkitt’s lymphoma.
With science stemming from the world’s most renowned
institutions and compassion that runs deep, Cornerstone strives to
improve the lives of people with rare cancers, inaugurating a new
era of hope. For more information, please visit
www.cornerstonepharma.com.
Safe Harbor StatementThis press release
contains forward-looking statements. These statements relate to
future events or the company’s future financial performance. In
some cases, you can identify forward-looking statements by
terminology such as "may", "will", "should", "expect", "plan",
"anticipate", "believe", "estimate", "predict", "potential" or
"continue", the negative of such terms, or other comparable
terminology. These statements are only predictions. Actual events
or results may differ materially from those in the forward-looking
statements as a result of various important factors. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, such statements should not be regarded
as a representation by the company, or any other person, that such
forward-looking statements will be achieved. The business and
operations of the company are subject to substantial risks which
increase the uncertainty inherent in forward-looking statements. We
undertake no duty to update any of the forward-looking statements,
whether as a result of new information, future events or otherwise.
In light of the foregoing, readers are cautioned not to place undue
reliance on such forward-looking statements.
Morrena Villanueva
cornerstone@antennagroup.com
(201) 465-8015
Rafael (NYSE:RFL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rafael (NYSE:RFL)
Historical Stock Chart
From Apr 2023 to Apr 2024